Massive Bio is an AI-powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development.
Our Involvement
Today, more than 90% of new drugs fail clinical trials, and those that do succeed take upwards of 7 years to reach FDA approval, involving over $2B in total expenditures per approved drug. Massive Bio aims to solve the broken clinical trial enrolment process, where pre-screening is restricted to major sites leading to only a 3% enrolment rate and 35% of trials are terminated because of under-enrollment resulting in patients not having access to the clinical trials and pharma companies spending significant time and budget to complete these trials.